Search

Your search keyword '"MESH : Twist Transcription Factor"' showing total 5 results
Start Over Descriptor "MESH : Twist Transcription Factor" Database OpenAIRE
5 results on '"MESH : Twist Transcription Factor"'

1. Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia

Author

Franck E. Nicolini, Sandrine Hayette, Ghassan Hamdan, Sandrine Jeanpierre, Francois-Xavier Mahon, Karen Sagorny, Alain Puisieux, Erika Cosset, Thibault Voeltzel, Charles Dumontet, Véronique Maguer-Satta, Laboratoire de Biophotonique et Pharmacologie - UMR 7213 ( LBP ), Centre National de la Recherche Scientifique ( CNRS ) -Réseau nanophotonique et optique, Université de Strasbourg ( UNISTRA ) -Université de Haute-Alsace (UHA) Mulhouse - Colmar ( Université de Haute-Alsace (UHA) ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Strasbourg ( UNISTRA ) -Université de Haute-Alsace (UHA) Mulhouse - Colmar ( Université de Haute-Alsace (UHA) ) -Centre National de la Recherche Scientifique ( CNRS ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon, Equipe 11, Centre Léon Bérard [Lyon]-Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Oncogénèse et progression tumorale, Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de Biologie Moléculaire, Hospices Civils de Lyon ( HCL ), Transfert de Genes a Visee Therapeutique Dans les Cellules Souches, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Equipe 14, Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), equipe 2, Institut Universitaire de France ( IUF ), Ministère de l'Éducation nationale, de l’Enseignement supérieur et de la Recherche ( M.E.N.E.S.R. ) -Ministère de l'Éducation nationale, de l’Enseignement supérieur et de la Recherche ( M.E.N.E.S.R. ) -Centre de Recherche en Cancérologie de Lyon ( CRCL ), Laboratoire de Biophotonique et Pharmacologie - UMR 7213 (LBP), Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA)), Université Claude Bernard Lyon 1 (UCBL), Centre Léon Bérard [Lyon]-Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospices Civils de Lyon (HCL), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Institut Universitaire de France (IUF), and Ministère de l'Education nationale, de l’Enseignement supérieur et de la Recherche (M.E.N.E.S.R.)-Ministère de l'Education nationale, de l’Enseignement supérieur et de la Recherche (M.E.N.E.S.R.)-Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL)

Subjects
MESH : RNA, Messenger, MESH: Piperazines, MESH : Pyrimidines, Antigens, CD34, Drug resistance, MESH : RNA, Small Interfering, Biochemistry, Piperazines, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Reverse Transcriptase Polymerase Chain Reaction, hemic and lymphatic diseases, MESH: RNA, Small Interfering, MESH: Protein Kinase Inhibitors, RNA, Small Interfering, 0303 health sciences, Reverse Transcriptase Polymerase Chain Reaction, MESH : Reverse Transcriptase Polymerase Chain Reaction, Nuclear Proteins, MESH: Twist Transcription Factor, Myeloid leukemia, MESH: Gene Expression Regulation, Neoplastic, Hematology, MESH: Drug Resistance, Neoplasm, 3. Good health, Gene Expression Regulation, Neoplastic, Leukemia, MESH : Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Benzamides, Imatinib Mesylate, MESH : Antigens, CD34, Tyrosine kinase, medicine.drug, MESH: Cell Line, Tumor, MESH : Gene Expression Regulation, Neoplastic, Immunology, [SDV.CAN]Life Sciences [q-bio]/Cancer, Biology, 03 medical and health sciences, Myelogenous, Cell Line, Tumor, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, medicine, Humans, RNA, Messenger, Protein Kinase Inhibitors, MESH: RNA, Messenger, 030304 developmental biology, MESH: Humans, Oncogene, MESH : Cell Line, Tumor, Twist-Related Protein 1, MESH : Twist Transcription Factor, MESH : Humans, MESH : Nuclear Proteins, Imatinib, MESH: Antigens, CD34, Cell Biology, MESH : Protein Kinase Inhibitors, medicine.disease, respiratory tract diseases, Pyrimidines, Imatinib mesylate, MESH: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Drug Resistance, Neoplasm, MESH: Pyrimidines, MESH : Piperazines, Cancer research, MESH : Leukemia, Myelogenous, Chronic, BCR-ABL Positive, MESH: Nuclear Proteins
Abstract

The mechanisms of resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) often remain obscure. Analysis of patient samples during disease progression revealed the up-regulation of the oncogene TWIST-1, also measured in primary samples from TKI-resistant patients. Moreover, we found that TWIST-1 was overexpressed in CML diagnostic samples of patients who later developed cytogenetic resistance to imatinib, even those without any detectable resistance mechanism. We confirmed the up-regulation of TWIST-1 at both RNA and protein levels in imatinib-resistant cell lines, irrespective of any other resistance mechanism. Analysis with specific small interfering RNA suggested TWIST-1 involvement in the resistance phenotype. Finally, the kinetics of TWIST-1 expression during the individual medical histories of CML patients indicated that TWIST-1 expression is down-regulated by TKIs and up-regulated with TKI resistance. We hypothesize that the overexpression of the TWIST-1 oncogene represents a novel key prognostic factor potentially useful for optimizing CML management in the TKI era.

Published
2011
Full Text
View/download PDF

2. Revisiting the canonical tumour progression model

Author

Anne-Pierre Morel, George W. Hinkal, Stéphane Ansieau, Alain Puisieux, equipe 2, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Oncogénèse et progression tumorale, Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Léon Bérard [Lyon]-Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Claude Bernard Lyon 1 (UCBL), Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Léon Bérard [Lyon]-Centre de Recherche en Cancérologie de Lyon ( CRCL ), and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS )

Subjects
Pathology, MESH: Oncogenes, MESH : Models, Biological, MESH : Tumor Escape, Metastasis, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Twist transcription factor, 0302 clinical medicine, Cell Movement, Neoplasms, MESH : Cell Movement, MESH: Neoplasms, Twist, MESH: Models, Theoretical, MESH: Cell Movement, ComputingMilieux_MISCELLANEOUS, 0303 health sciences, MESH: Twist Transcription Factor, General Medicine, MESH : Epithelial-Mesenchymal Transition, Cell Transformation, Neoplastic, 030220 oncology & carcinogenesis, Disease Progression, MESH: Tumor Escape, MESH: Disease Progression, medicine.medical_specialty, Epithelial-Mesenchymal Transition, [SDV.CAN]Life Sciences [q-bio]/Cancer, Biology, Models, Biological, 03 medical and health sciences, Text mining, medicine, Humans, Epithelial–mesenchymal transition, 030304 developmental biology, MESH : Oncogenes, MESH: Humans, business.industry, MESH : Models, Theoretical, Disease progression, Twist-Related Protein 1, MESH : Twist Transcription Factor, MESH : Humans, MESH: Models, Biological, MESH : Cell Transformation, Neoplastic, Cell movement, Oncogenes, MESH : Disease Progression, Models, Theoretical, medicine.disease, MESH : Neoplasms, MESH: Epithelial-Mesenchymal Transition, Tumor Escape, MESH: Cell Transformation, Neoplastic, Cancer research, business
Abstract

International audience

Published
2011
Full Text
View/download PDF

3. [An alternate model of tumoral progression]

Author

Ansieau , Stéphane, Puisieux , Alain, equipe 2, Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut Universitaire de France ( IUF ), Ministère de l'Éducation nationale, de l’Enseignement supérieur et de la Recherche ( M.E.N.E.S.R. ) -Ministère de l'Éducation nationale, de l’Enseignement supérieur et de la Recherche ( M.E.N.E.S.R. ) -Centre de Recherche en Cancérologie de Lyon ( CRCL ), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Universitaire de France (IUF), and Ministère de l'Education nationale, de l’Enseignement supérieur et de la Recherche (M.E.N.E.S.R.)-Ministère de l'Education nationale, de l’Enseignement supérieur et de la Recherche (M.E.N.E.S.R.)-Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL)

Subjects
MESH : Cell Aging, [SDV.CAN]Life Sciences [q-bio]/Cancer, Apoptosis, MESH : Models, Biological, Environment, Models, Biological, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Animals, Humans, MESH: Animals, Neoplasm Metastasis, MESH: Environment, Cellular Senescence, MESH: Humans, MESH: Apoptosis, Twist-Related Protein 1, MESH : Humans, MESH : Twist Transcription Factor, MESH: Models, Biological, MESH: Twist Transcription Factor, MESH : Cell Transformation, Neoplastic, MESH: Neoplasm Metastasis, MESH : Environment, Cell Transformation, Neoplastic, MESH: Cell Aging, MESH: Cell Transformation, Neoplastic, MESH : Neoplasm Metastasis, MESH : Animals, MESH : Apoptosis
Abstract

International audience; Tumor development is usually described as the result of successive waves of genetic and epigenetic changes and of Darwinian selections that allow the progressive emergence of cells with proliferation and survival advantages. According to this model of tumoral progression, the acquisition of metastatic properties is perceived as a late stage-induced response to environmentally damaging conditions in the tumor, in particular oxygen and nutriment lack. Analyzing the consequences linked to the reactivation of embryonic programmes leads, for some cancer types, to question the linearity of this model, by showing that the dissemination of cancerous or precancerous cells may begin as early as the lesions convert from a premalignant to a malignant state. We propose to review the main findings that brought about these conclusions and to discuss what consequences they might have.

Published
2011
Full Text
View/download PDF

4. TWISTing an embryonic transcription factor into an oncoprotein

Author

Stéphane Ansieau, Jérémy Bastid, Anne-Pierre Morel, George W. Hinkal, Alain Puisieux, equipe 2, Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Oncogénèse et progression tumorale, Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Cancer Research, Poor prognosis, [SDV.CAN]Life Sciences [q-bio]/Cancer, Biology, medicine.disease_cause, Bioinformatics, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 03 medical and health sciences, MESH: Oncogene Proteins, 0302 clinical medicine, Genetics, medicine, Animals, Humans, MESH : Embryonic Stem Cells, MESH: Animals, MESH: Embryonic Stem Cells, Twist Protein, Molecular Biology, Transcription factor, Embryonic Stem Cells, 030304 developmental biology, Oncogene Proteins, 0303 health sciences, MESH: Humans, MESH : Oncogene Proteins, Twist-Related Protein 1, MESH : Humans, MESH : Twist Transcription Factor, MESH: Twist Transcription Factor, Embryonic stem cell, 3. Good health, 030220 oncology & carcinogenesis, Cancer research, MESH : Animals, Carcinogenesis
Abstract

International audience; Over the past decade, the reactivation of TWIST embryonic transcription factors has been described as a frequent event and a marker of poor prognosis in an impressive array of human cancers. Growing evidence now supports the premise that these cancers hijack TWIST's embryonic functions, granting oncogenic and metastatic properties. In this review, we report on the history and recent breakthroughs in understanding TWIST protein functions and the emerging role of the associated epithelial-mesenchymal transition (EMT) in tumorigenesis. We then broaden the discussion to address the general contribution of reactivating embryonic programs in cancerogenesis.

Published
2010
Full Text
View/download PDF

5. The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status

Author

Jean P. Thiery, Hugues Bittard, Marie E. Fondrevelle, Franck Monnien, Hervé Wallerand, Robert E. Reiter, Dominique Chopin, Bernadette Kantelip, Laboratoire d'anatomie pathologique [Besancon], Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz-Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Service de Néphrologie et Urologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Service d'urologie, andrologie et transplantation rénale, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Service d'Anatomie pathologique [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), and Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques

Subjects
Oncology, Male, Pathology, MESH : Immunohistochemistry, MESH : Aged, Kaplan-Meier Estimate, MESH: Cadherins, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Proportional Hazards Models, 0302 clinical medicine, MESH: Aged, 80 and over, MESH: Risk Factors, Risk Factors, MESH : Neoplasm Staging, MESH : Female, MESH: Kaplan-Meiers Estimate, Stage (cooking), MESH: Aged, Aged, 80 and over, 0303 health sciences, MESH: Middle Aged, MESH : Prognosis, Smoking, MESH: Twist Transcription Factor, Nuclear Proteins, Anatomical pathology, MESH: Neoplasm Staging, Middle Aged, Cadherins, Prognosis, Immunohistochemistry, MESH : Risk Factors, 3. Good health, MESH: Urinary Bladder Neoplasms, MESH : Smoking, MESH : Urinary Bladder Neoplasms, 030220 oncology & carcinogenesis, Disease Progression, MESH: Disease Progression, Female, MESH : Cadherins, medicine.medical_specialty, MESH: Smoking, Urology, MESH : Male, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Multivariate Analysis, MESH: Prognosis, 03 medical and health sciences, Internal medicine, medicine, Humans, MESH : Middle Aged, Epithelial–mesenchymal transition, Risk factor, MESH : Aged, 80 and over, 030304 developmental biology, Aged, Neoplasm Staging, Proportional Hazards Models, Bladder cancer, MESH: Humans, Proportional hazards model, business.industry, Twist-Related Protein 1, MESH : Twist Transcription Factor, MESH : Humans, Cancer, MESH : Multivariate Analysis, MESH : Nuclear Proteins, MESH: Immunohistochemistry, MESH : Kaplan-Meiers Estimate, MESH : Disease Progression, medicine.disease, MESH : Proportional Hazards Models, MESH: Male, Urinary Bladder Neoplasms, Multivariate Analysis, business, MESH: Nuclear Proteins, MESH: Female
Abstract

International audience; OBJECTIVES: Twist is considered as transcription factor that regulates epithelial mesenchymal transition (EMT) by at least inhibition of E-cadherin expression. EMT is a key event in the tumor invasion process. The purpose of this study is to investigate the expression of Twist but also those of E- and N-cadherin in human primary bladder tumor and to evaluate its prognostic value. As smoking cigarettes is a strong bladder cancer risk factor, we tried to evaluate the impact of the tobacco status on these molecular abnormalities. MATERIALS AND METHODS: To delineate on the oncogenic role for Twist in human bladder cancer, we evaluated the E- and N-cadherin but also Twist expression (n = 70) by immunohistochemistry. We evaluated the prognostic value of these expressions. Moreover, we tried to correlate these protein expressions to the smoking status of the patients. Overall survival (OS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method, and multivariate analysis was performed using the Cox proportional hazard analysis. RESULTS: Of the 70 bladder tumors, 28 (40%) cases were positive for Twist expression, 16 (23%) cases were negative for E-cadherin expression, and 12 (17%) were positive for N-cadherin expression. When categorized into negative vs. positive expression, Twist was associated with the stage (P = 0.001), the grade (P < 0.001), the progression (P = 0.02), and the E-cadherin expression (P = 0.01). Moreover, positive Twist expression clearly predicted poorer PFS (P = 0.02). In the multivariate analysis, both positive Twist expression and loss of E-cadherin expression were independent prognostic factors for PFS (P = 0.046 and P = 0.001, respectively) and only loss of E-cadherin expression for the OS (P < 0.001). We also demonstrated that almost 60% (16/28) of patients with Twist-positive expression were current smokers at the time of the diagnosis, corroborating the fact that smoking modulates the expression of EMT markers including Twist. CONCLUSION: Positive Twist expression may be a useful prognostic marker for patients with bladder cancer. Its expression seems to be correlated to the tobacco status of the patients.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results